Our findings delineate a novel USP20‐STUB1‐CTSL axis that drives HNSCC progression, underscoring USP20 as a promising therapeutic target for mitigating metastasis and enhancing treatment efficacy in HNSCC. Here, USP20 is linked to head and neck squamous cell carcinoma.